Primary Progressive Aphasia With Suspected Alzheimer's Disease Clinical Trial
Official title:
Tau PET Imaging in Atypical Dementias
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
| Status | Recruiting |
| Enrollment | 70 |
| Est. completion date | March 30, 2024 |
| Est. primary completion date | March 30, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years to 100 Years |
| Eligibility | Inclusion Criteria: - Must have primary progressive aphasia Exclusion Criteria: - Pregnancy - Breastfeeding - Receiving radiation clinically |
| Country | Name | City | State |
|---|---|---|---|
| United States | Cognitive Neurology and Alzheimer's Disease Center - Northwestern University | Chicago | Illinois |
| Lead Sponsor | Collaborator |
|---|---|
| Northwestern University | National Institute on Aging (NIA) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Tau levels in PPA participants | Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions. | 2 years |